VIPAS39: A Protein Potential Drug Target (G63894)

Target Name: VIPAS39

NCBI ID: G63894

VIPAS39

VIPAS39: A Protein Potential Drug Target

VIPAS39 (VPS33B-interacting protein) is a protein that is expressed in various cell types, including neurons, and is involved in the regulation of cell polarity and apical restriction.VIPAS39 has been identified as a potential drug target and has been shown to play a role in the development and progression of various diseases, including cancer.

Polarity and Apical Restriction

VIPAS39 is involved in the regulation of cell polarity, which is the ability of cells to differentiate into specific cell types. During the cell cycle, cells go through different stages, including G1, S, G2, and M, and each stage is characterized by a specific level of differentiation. For example, during the S stage, cells are ready to differentiate into the specific cell type that they will become.

VIPAS39 plays a role in the regulation of cell polarity by ensuring that the cell maintains its integrity and stability. It does this by interacting with the cytoskeleton and the actin cytoskeleton, which are responsible for the structure and stability of the cell.

VIPAS39 also regulates apical restriction, which is the process by which cells stick to the surface of a tissue and prevent themselves from moving away. This is important for the development and maintenance of tissues and organs, as well as for the treatment of various diseases.

VIPAS39 and Disease

VIPAS39 has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that VIPAS39 is involved in the development of brain tumors, and that it promotes the growth and progression of cancer cells.

In addition to its role in the development of cancer, VIPAS39 has also been shown to be involved in the progression of other diseases, including neurodegenerative disorders and autoimmune diseases. For example, studies have shown that VIPAS39 is involved in the development of Alzheimer's disease and that it promotes the growth and progression of neurodegenerate disorders.

Drug Target

VIPAS39 is a potential drug target because of its involvement in the regulation of cell polarity and apical restriction. Drugs that target VIPAS39 have been shown to be effective in treating various diseases, including cancer and neurodegenerative disorders.

One class of drugs that have been shown to target VIPAS39 is the small molecule inhibitors of the protein. These drugs work by binding to VIPAS39 and preventing it from interacting with its downstream targets.

Another class of drugs that have been shown to target VIPAS39 are the monoclonal antibodies. These drugs work by binding to VIPAS39 and targeting the protein within the cell.

Conclusion

VIPAS39 is a protein that is involved in the regulation of cell polarity and apical restriction. It has been identified as a potential drug target and is being studied for its role in the development and progression of various diseases, including cancer. Further research is needed to fully understand the role of VIPAS39 and to develop effective treatments.

Protein Name: VPS33B Interacting Protein, Apical-basolateral Polarity Regulator, Spe-39 Homolog

Functions: Proposed to be involved in endosomal maturation implicating in part VPS33B. In epithelial cells, the VPS33B:VIPAS39 complex may play a role in the apical RAB11A-dependent recycling pathway and in the maintenance of the apical-basolateral polarity (PubMed:20190753). May play a role in lysosomal trafficking, probably via association with the core HOPS complex in a discrete population of endosomes; the functions seems to be independent of VPS33B (PubMed:19109425). May play a role in vesicular trafficking during spermatogenesis (By similarity). May be involved in direct or indirect transcriptional regulation of E-cadherin (By similarity)

The "VIPAS39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VIPAS39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets